Selçuk YÜKSEL, Ceyhun ACARİ, Gülçin OTAR YENER, Serkan TÜRKUÇAR, Hatice ADIGÜZEL DÜNDAR, Balahan MAKAY, Erbil ÜNSAL

Comparison of Different Pharmaceutical Preparations of Colchicine in Children with Familial Mediterranean Fever: Is Colchicine Opocalcium a Good Alternative?

Background: Colchicine is an anti-inflammatory agent used for preventing familial Mediterranean fever (FMF) attacks and amyloidosis. A significant number of patients are non-responsive or intolerant to the domestic drug colchicum dispert.Aims: To compare the efficacy and side effects of colchicum dispert and colchicine opocalcium in children with FMF.Study Design: A total of 29 children with FMF who used colchicum dispert for at least 6 months initially and colchicine opocalcium for another consecutive 6 months were included. Sex and gender equity in research was considered. Clinical features, visual analog scale for pain scores, exercise-induced leg pain, and FMF severity scores with laboratory parameters were evaluated for both the treatment periods. Bristol stool chart and number of stools per 24 hours were recorded to compare the gastrointestinal side effects.Methods: A total of 29 children with FMF who used colchicum dispert for at least 6 months initially and colchicine opocalcium for another consecutive 6 months were included. Sex and gender equity in research was considered. Clinical features, visual analog scale for pain scores, exercise-induced leg pain, and FMF severity scores with laboratory parameters were evaluated for both the treatment periods. Bristol stool chart and number of stools per 24 hours were recorded to compare the gastrointestinal side effects.Results: The major indication was non-responsiveness in 18 patients (62%) and intolerance in 11 patients (38%). Usage of colchicine opocalcium (significantly higher dosage than colchicum dispert) showed statistically significant beneficial effects on the number and duration of attacks, visual analog scale for pain, exercise-induced leg pain scores, and FMF severity scores (p

PDF

___

1.Ozen S, Batu ED. The Myths We Believed in Familial Mediterranean Fever: What Have We Learned in the Past Years? Semin Immunopathol 2015;37:363-9. [Crossref]
2.Alkadi H, Khubeiz MJ, Jbeily R. Colchicine: A Review on Chemical Structure and Clinical Usage. Infect Disord Drug Targets 2018;18:105-21. [Crossref]
3.Ozkan E. A New Approach to the Treatment of Periodic Fever. Med Bull Istanbul 1972;5:44-9.
4.Goldfinger SE. Colchicine for Familial Mediterranean Fever. N Engl J Med 1972;287:1302. [Crossref]
5.Goldberg O, Levinsky Y, Peled O, Koren G, Harel L, Amarilyo G. Age dependent safety and efficacy of Colchicine Treatment for Familial Mediterranean Fever in Chil-dren. Semin Arthritis Rheum 2019;49:459-63. [Crossref]
6.Ozen S, Kone-Paut I, Gül A. Colchicine Resistance and Intolerance in Familial Mediterranean Fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47:115-20. [Crossref]
7.Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, et al. Familial Mediter-ranean Fever in Childhood: A Single-Center Experience. Rheumatol Int 2018;38:67-74.[Crossref]
8.Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incom-plete Response to Colchicine in M694V Homozygote FMF Patients. Autoimmun Rev 2012;12:72-6. [Crossref]
9.Gül A. Approach to the Patients with Inadequate Response to colchicine in Familial Mediterranean Fever. Best Pract Res Clin Rheumatol 2016;30:296-303. [Crossref]
10.Heidari S, Babor TF, Castro P, Tort S, Curno M. Equidade de Sexo e Gênero na Pesquisa: Fundamentação Das Diretrizes SAGER e uso recomendado [Sex and Gen-der Equity in Research: Rationale for the SAGER Guidelines and Recommended Use]. Epidemiol Serv Saude 2017;26:665-75. [Crossref]
11.Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A New Set of Criteria for the Diagnosis of Familial Mediterranean Fever in Childhood. Rheumatol-ogy (Oxford) 2009;48:395-8. [Crossref]
12.Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF Arthritis Vasculitis and Orphan Disease Research in Pediatric Rheumatology (FAVOR) and Turkish FMF Study Group. FMF50: A Score for Assessing Outcome in familial Med-iterranean Fever. Ann Rheum Dis 2014;73:897-901.[Crossref]
13.Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, et al. Clinical Differences between North African and Iraqi Jews with Familial Mediterranean Fever. Am J Med Genet 1998;75:216-9.
14.Gulati R, Komuravelly A, Leb S, Mhanna MJ, Ghori A, Leon J, et al. Usefulness of Assessment of Stool Form by the Modified Bristol Stool Form Scale in Primary Care Pediatrics. Pediatr Gastroenterol Hepatol Nutr 2018;21:93-100. [Crossref]
15.Amarenco G. Bristol Stool Chart: Prospective and Monocentric Study of "Stools In-trospection" in Healthy Subjects. Prog Urol 2014;24:708-13. [Crossref]
16.Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, et al. Correlation of Endoscopic Disease Severity with Pediatric Ulcerative Colitis Activity Index Score in Children and Young Adults with Ulcerative colitis. World J Gastroenterol 2017;23:3322-9. [Crossref]
17.Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of Colchicine-Resistant Famil-ial Mediterranean Fever in Children and Adolescents. Rheumatol Int 2015;35:1733-7. [Crossref]
18.Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016;75:644-51. [Crossref]
19.Emmungil H, İlgen U, Turan S, Yaman S, Küçükşahin O. Different Pharmaceutical Preparations of Colchicine for Familial Mediterranean Fever: Are They The same? Rheumatol Int 2020;40:129-35. [Crossref]
20.Baglan E, Ozdel S, Bulbul M. Do All Colchicine Preparations Have the Same Effec-tiveness in Patients with Familial Mediterranean Fever? Mod Rheumatol 2020;1-4. [Crossref]
21.Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse Events During Oral Colchicine Use: A Systematic Review and Meta-Analysis of Randomised Con-trolled Trials. Arthritis Res Ther 2020;22:28. [Crossref]